The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
Leukemia, 08/01/2012
Dimopoulos MA et al. – Bortezomib–based therapies may be more appropriate for the initial management of patients with myeloma–related renal failure; however, thalidomide and lenalidomide are also associated with significant probability of improvement of their renal function.



